
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4702032/publications.pdf Version: 2024-02-01



KENC SHEN

#	Article	IF	CITATIONS
1	Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of Proteomics, 2013, 80, 171-182.	2.4	254
2	The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget, 2015, 6, 25520-25532.	1.8	81
3	Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biology and Medicine, 2013, 10, 138-41.	3.0	80
4	Characterization of exosomes derived from ovarian cancer cells and normal ovarian epithelial cells by nanoparticle tracking analysis. Tumor Biology, 2016, 37, 4213-4221.	1.8	74
5	Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. International Journal of Oncology, 2018, 53, 2637-2646.	3.3	58
6	Comparative study of ovarian clearÂcell carcinoma with and without endometriosis in People's Republic of China. Fertility and Sterility, 2014, 102, 1656-1662.	1.0	42
7	miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. Oncology Reports, 2014, 31, 1905-1910.	2.6	40
8	Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. Journal of Cellular and Molecular Medicine, 2016, 20, 581-593.	3.6	39
9	Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Journal of Gynecologic Oncology, 2017, 28, e39.	2.2	36
10	Laparoscopic vs. Open Abdominal Radical Hysterectomy for Cervical Cancer: A Single-Institution, Propensity Score Matching Study in China. Frontiers in Oncology, 2019, 9, 1107.	2.8	35
11	Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World Journal of Surgical Oncology, 2017, 15, 154.	1.9	30
12	Computerized tomography angiography in preoperative assessment of intravenous leiomyomatosis extending to inferior vena cava and heart. BMC Cancer, 2016, 16, 73.	2.6	29
13	Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience. International Journal of Clinical Oncology, 2019, 24, 712-720.	2.2	29
14	Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy. Journal of Ovarian Research, 2018, 11, 64.	3.0	28
15	Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression. Oncotarget, 2018, 9, 12064-12078.	1.8	27
16	<i>JAM3</i> methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget, 2015, 6, 44373-44387.	1.8	27
17	Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study. BMC Cancer, 2015, 15, 270.	2.6	26
18	Inhibition of the long non-coding RNA MALAT1 suppresses tumorigenicity and induces apoptosis in the human ovarian cancer SKOV3 cell line. Oncology Letters, 2016, 11, 3686-3692.	1.8	26

#	Article	IF	CITATIONS
19	Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors. Gynecologic Oncology, 2018, 151, 275-281.	1.4	26
20	Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing. Journal of Ovarian Research, 2018, 11, 31.	3.0	26
21	Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins. OncoTargets and Therapy, 2014, 7, 1705.	2.0	25
22	Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing. Frontiers in Oncology, 2019, 9, 123.	2.8	24
23	Clear cell carcinoma of the uterine cervix: clinical characteristics and feasibility of fertility-preserving treatment. OncoTargets and Therapy, 2014, 7, 111.	2.0	23
24	Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2173-2183.	2.5	23
25	Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. Gynecologic Oncology, 2016, 143, 526-531.	1.4	23
26	<p>Progress in immunocytochemical staining for cervical cancer screening</p> . Cancer Management and Research, 2019, Volume 11, 1817-1827.	1.9	23
27	Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. International Journal of Clinical and Experimental Pathology, 2014, 7, 848-57.	0.5	23
28	Conservative treatment and long-term follow up of endodermal sinus tumor of the vagina. Gynecologic Oncology, 2012, 125, 358-361.	1.4	22
29	Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data. Scientific Reports, 2019, 9, 9924.	3.3	22
30	Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 1147.	2.8	22
31	Fertility-sparing surgery for patients with low-grade endometrial stromal sarcoma. Oncotarget, 2017, 8, 10602-10608.	1.8	22
32	Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor. Gynecologic Oncology, 2014, 134, 78-83.	1.4	21
33	Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer. Frontiers in Genetics, 2019, 10, 839.	2.3	21
34	Characteristic and Prognostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study. PLoS ONE, 2015, 10, e0121818.	2.5	21
35	The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget, 2016, 7, 15566-15576.	1.8	21
36	Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. Cancer Management and Research, 2018, Volume 10, 4915-4928.	1.9	19

#	Article	IF	CITATIONS
37	DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions. International Journal of Clinical and Experimental Pathology, 2015, 8, 14939-45.	0.5	19
38	Single-Port vs Multiport Laparoscopic Hysterectomy: A Meta-Analysis of Randomized Controlled Trials. Journal of Minimally Invasive Gynecology, 2016, 23, 1049-1056.	0.6	18
39	Is adjuvant chemotherapy beneficial for patients with FIGO stage IC adult granulosa cell tumor of the ovary?. Journal of Ovarian Research, 2018, 11, 25.	3.0	18
40	Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study. Cancer Management and Research, 2018, Volume 10, 6913-6920.	1.9	17
41	Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. BMC Cancer, 2019, 19, 1095.	2.6	17
42	The potential for less radical surgery in women with stage IA2–IB1 cervical cancer. International Journal of Gynecology and Obstetrics, 2015, 130, 235-240.	2.3	16
43	Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells. Tumor Biology, 2016, 37, 15763-15771.	1.8	16
44	Protocol for a multicentre, multistage, prospective study in China using system-based approaches for consistent improvement in surgical safety. BMJ Open, 2017, 7, e015147.	1.9	16
45	Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience. Gynecologic Oncology, 2020, 157, 94-100.	1.4	16
46	Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS ONE, 2015, 10, e0133498.	2.5	16
47	Primary endometrioid stromal sarcomas of the ovary: a clinicopathological study of 14 cases with a review of the literature. Oncotarget, 2017, 8, 63345-63352.	1.8	15
48	Fourier Transform Infrared Spectroscopy: An Innovative Method for the Diagnosis of Ovarian Cancer. Cancer Management and Research, 2021, Volume 13, 2389-2399.	1.9	15
49	Analysis of treatment modalities and prognosis on microinvasive cervical cancer: a 10-year cohort study in China. Journal of Gynecologic Oncology, 2014, 25, 293.	2.2	14
50	Splenectomy during cytoreductive surgery in epithelial ovarian cancer. Cancer Management and Research, 2018, Volume 10, 3473-3482.	1.9	14
51	Uterine Adenosarcoma: A Retrospective 12-Year Single-Center Study. Frontiers in Oncology, 2019, 9, 237.	2.8	13
52	Fertility-Sparing Treatment in Young Patients With Grade 2 Presumed Stage IA Endometrioid Endometrial Adenocarcinoma. Frontiers in Oncology, 2020, 10, 1437.	2.8	13
53	Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. Journal of Ovarian Research, 2021, 14, 12.	3.0	13
54	Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery. International Journal of Gynecological Cancer, 2020, 30, 664-669.	2.5	12

#	Article	IF	CITATIONS
55	The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis. PLoS ONE, 2015, 10, e0138692.	2.5	11
56	Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. Journal of Cynecologic Oncology, 2016, 27, e40.	2.2	11
57	Piver Type II vs. Type III Hysterectomy in the Treatment of Early-Stage Cervical Cancer: Midterm Follow-up Results of a Randomized Controlled Trial. Frontiers in Oncology, 2018, 8, 568.	2.8	10
58	Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer. Journal of Ovarian Research, 2018, 11, 40.	3.0	10
59	Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery. Journal of Gynecologic Oncology, 2020, 31, e16.	2.2	10
60	Efficacy of neoadjuvant cisplatin and 5-flourouracil prior to surgery in FIGO stage IB2/IIA2 cervical cancer. Molecular and Clinical Oncology, 2014, 2, 240-244.	1.0	9
61	Accuracy of conization procedure for predicting pathological parameters of radical hysterectomy in stage Ia2–Ib1 (â‰⊉ cm) cervical cancer. Scientific Reports, 2016, 6, 25992.	3.3	9
62	Clinicopathological characteristics and prognosis of adult ovarian granulosa cell tumor: a single-institution experience in China. OncoTargets and Therapy, 2018, Volume 11, 1315-1322.	2.0	9
63	Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma. Journal of Ovarian Research, 2017, 10, 67.	3.0	8
64	Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma. Journal of Ovarian Research, 2017, 10, 63.	3.0	8
65	Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experience. Journal of Ovarian Research, 2020, 13, 128.	3.0	8
66	Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors. Oncologist, 2020, 25, e1396-e1405.	3.7	8
67	<p>Fourier Transform Infrared Spectroscopy Monitoring of Dihydroartemisinin-Induced Growth Inhibition in Ovarian Cancer Cells and Normal Ovarian Surface Epithelial Cells</p> . Cancer Management and Research, 2020, Volume 12, 653-661.	1.9	8
68	Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients. OncoTargets and Therapy, 2021, Volume 14, 809-822.	2.0	8
69	Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases. Archives of Gynecology and Obstetrics, 2021, 304, 1043-1053.	1.7	8
70	Safety and efficacy of bleomycin/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. Oncotarget, 2017, 8, 15952-15960.	1.8	8
71	Tumor heterogeneity has important consequences for personalized medicine in ovarian cancer. Histology and Histopathology, 2015, 30, 173-81.	0.7	8
72	Tailored therapy and long-term surveillance of malignant germ cell tumors in the female genital system: 10-year experience. Journal of Gynecologic Oncology, 2016, 27, e26.	2.2	7

#	Article	IF	CITATIONS
73	Occult invasive cervical cancer after simple hysterectomy: a multi-center retrospective study of 89 cases. BMC Cancer, 2016, 16, 507.	2.6	7
74	The effects of hysterectomy with bilateral salpingectomy on ovarian reserve. International Journal of Gynecology and Obstetrics, 2019, 145, 233-238.	2.3	7
75	CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity. Frontiers in Cell and Developmental Biology, 2020, 8, 561804.	3.7	7
76	Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods. PLoS ONE, 2021, 16, e0253136.	2.5	7
77	Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy. Frontiers in Oncology, 2021, 11, 738370.	2.8	7
78	The proteomic comparison of peripheral circulation-derived exosomes from the epithelial ovarian carcinoma (EOC) patients and non-EOC subjects. Translational Cancer Research, 2019, 8, 452-465.	1.0	7
79	Role of Exosome Shuttle RNA in Cell-to-Cell Communication. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae, 2016, 38, 480-3.	0.2	7
80	Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity. Frontiers in Oncology, 2022, 12, 812346.	2.8	7
81	Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. Journal of Ovarian Research, 2014, 7, 121.	3.0	6
82	Conservative management of primary vaginal endodermal sinus tumor and rhabdomyosarcoma. Oncotarget, 2017, 8, 63453-63460.	1.8	6
83	Identification of potential key genes associated with ovarian clear cell carcinoma. Cancer Management and Research, 2018, Volume 10, 5461-5470.	1.9	6
84	Uterine and Cervical Adenosarcoma: A Retrospective Study of Overall Oncologic Outcomes and Fertility Preservation in Early-Stage Disease. Oncologist, 2019, 24, e870-e879.	3.7	6
85	Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Oncotarget, 2017, 8, 15136-15148.	1.8	6
86	Anti-Müllerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study. Oncotarget, 2017, 8, 113920-113927.	1.8	6
87	Neoadjuvant chemotherapy in locally advanced cervical carcinoma: which is better, intravenous or intra-arterial?. OncoTargets and Therapy, 2014, 7, 2155.	2.0	5
88	Adenocarcinoma of the ascending colon in a 31-year-old pregnant woman. Medicine (United States), 2018, 97, e13707.	1.0	5
89	Analysis of Outcomes and Prognostic Factors after Fertility-Sparing Surgery in Patients with Early Stage Juvenile Granulosa Cell Tumor of the Ovary: Experience from a Tertiary Center. Journal of Pediatric and Adolescent Gynecology, 2022, 35, 486-491.	0.7	5
90	Selective suppression of autocatalytic caspase-3 driven by two-step transcriptional amplified human telomerase reverse transcriptase promoter on ovarian carcinoma growth in vitro and in mice. Oncology Reports, 2014, 32, 225-234.	2.6	4

#	Article	IF	CITATIONS
91	Highâ€risk human papillomavirus infection clearance following conization among patients with cervical intraepithelial neoplasm grade 3 aged at least 45Âyears. International Journal of Gynecology and Obstetrics, 2017, 136, 47-52.	2.3	4
92	Identification of Somatic Mutations in Papanicolaou Smear DNA and Plasma Circulating Cell-Free DNA for Detection of Endometrial and Epithelial Ovarian Cancers: A Pilot Study. Frontiers in Oncology, 2020, 10, 582546.	2.8	4
93	Magnetic resonance imaging is useful for diagnosis and evaluation of recurrent intravenous leiomyomatosis before surgery. Fertility and Sterility, 2009, 92, 1150-1152.	1.0	3
94	Outcomes and prognostic factors of patients with recurrent and persistent malignant ovarian germ cell tumors. Archives of Gynecology and Obstetrics, 2020, 301, 1021-1026.	1.7	3
95	<p>Importance of Standard Treatment in Prognosis of Patients with Ovarian Cancer and Associated Cerebral Infarction</p> . Clinical Interventions in Aging, 2020, Volume 15, 151-157.	2.9	3
96	Analysis of 30 patients with persistent or recurrent squamous cell carcinoma of the cervix within one year after concurrent chemoradiotherapy. Cancer Biology and Medicine, 2013, 10, 227-31.	3.0	3
97	Aptamer-based radioimmunotherapy: the feasibility and prospect in cancer therapy. Journal of Radioanalytical and Nuclear Chemistry, 2011, 290, 453-457.	1.5	2
98	B-cell-specific Moloney murine leukemia virus integration site 1: potential stratification factor and therapeutic target for epithelial ovarian cancer. OncoTargets and Therapy, 2016, Volume 9, 5203-5208.	2.0	2
99	Malignant mixed ovarian germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case report. OncoTargets and Therapy, 2018, Volume 11, 6853-6862.	2.0	2
100	<clinicopathological and="" by<br="" characteristics="" complicated="" of="" outcomes="" pregnancy="" treatment="">Malignant Ovarian Germ Cell Tumors. Cancer Management and Research, 2020, Volume 12, 1347-1354.</clinicopathological>	1.9	2
101	Tumor Volume Predicts High-Risk Patients and Guides Initial Chemoradiotherapy for Early Cervical Cancer. Frontiers in Oncology, 2021, 11, 640846.	2.8	2
102	Detection of recurrent cervical cancer by whole-body FDG PET scans. Chinese Journal of Clinical Oncology, 2008, 5, 125-127.	0.0	1
103	Protective effect of gonadotropin-releasing hormone analog on the ovarian reserve in rats receiving cyclophosphamide treatment. OncoTargets and Therapy, 2015, 8, 661.	2.0	1
104	<p>Postchemotherapy sarcoma as a somatic-type malignancy derived from the gonadal yolk sac tumor in a patient with 46, XY pure gonadal dysgenesis</p> . OncoTargets and Therapy, 2019, Volume 12, 2365-2372.	2.0	1
105	Could Adjuvant Chemotherapy Improve Prognosis for Cervical Cancer Patients with Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?. Risk Management and Healthcare Policy, 2021, Volume 14, 109-116.	2.5	1
106	Evaluation of Cervical High-Grade Squamous Intraepithelial Lesions-Correlated Markers as Triage Strategy for Colposcopy After Co-Testing. OncoTargets and Therapy, 2021, Volume 14, 2075-2084.	2.0	1
107	MRI-based three-dimensional reconstruction for staging cervical cancer and predicting high-risk patients. Annals of Translational Medicine, 2021, 9, 1398-1398.	1.7	1
108	Clinicopathological features and maternal and foetal management of pregnancy‑complicating Krukenberg tumours. Molecular and Clinical Oncology, 2020, 12, 581-587.	1.0	1

#	Article	IF	CITATIONS
109	Pegylated liposomal doxorubicin as a single agent or as combination therapy with carboplatin in patients with recurrent or refractory epithelial ovarian cancer. Clinical Oncology and Cancer Research, 2009, 6, 387-393.	0.1	Ο
110	A single-center retrospective long-term analysis of 80 cases of ovarian Sertoli-Leydig cell tumors. Chinese Medical Journal, 2021, Publish Ahead of Print, 2373-2375.	2.3	0